@article{9e1e1ab5be5240e4a4536442a1e84911,
title = "End Points for Clinical Trials in Hyperoxaluria: Case Study of Patient-Focused Drug Development in a Rare Disease",
author = "Lieske, {John C.} and Malley, {Meaghan A.} and Melissa West and Kim Hollander and Milliner, {Dawn S.}",
note = "Funding Information: Dr Milliner has received consulting fees from OxThera, Dicerna, Allena, Synlogic, and Alnylam, and grant funding from OxThera and Alnylam. Dr Lieske has received consulting fees from Alnylam, OxThera, Dicerna, Synlogic, Orfan-Bridgebio, and Novobiome, and grant support from Alnylam, Allena, Retrophin, OxThera, and Dicerna. Meaghan Malley and Melissa West are employed by the ASN. Kim Hollander is Executive Director of the OHF. Funding Information: The authors were partially supported by the Rare Kidney Stone Consortium (RKSC; U54DK83908), which is part of Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), R21TR003174, and the Mayo Foundation. The Patient Focussed Drug Development meeting was funded by the OHF. The KHI is funded by the ASN and is a public-private partnership between the ASN, the FDA, and over 100 member companies and organizations. ",
year = "2022",
month = may,
doi = "10.1053/j.ajkd.2021.09.005",
language = "English (US)",
volume = "79",
pages = "754--756",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "5",
}